Acinetobacter baumannii is a common pathogen and the emerged antibiotic resistance has been steadily spreading recently. Due to the rapid development of antibiotic resistance, infection with A. baumannii is difficult to treat, and it has been recognized as a global public health threat. Effective treatments for A. baumannii infection are limited because the molecular epidemiology and antibiotic resistance mechanism are not well elucidated, leading to increased mortality rates and healthcare costs.
In recent years, there have been increasing reports of MDR and XDR A. baumannii infection worldwide. Several known pathogenic factors, including lipopolysaccharide, capsular polysaccharides, protein secretion systems, efflux pumps and biofilm formation, have been reported to be involved in antibiotic resistance, environmental persistence, host-pathogen interactions, and immune evasion. However, the specific mechanism remains unclear.
The exploration of the molecular epidemiology and antibiotic resistance mechanisms of A. baumannii is of great significance for the therapeutic development of A. baumannii infection.
This Research Topic focuses on the molecular epidemiology and antibiotic resistance mechanism of A. baumannii to novel antibacterial drugs, including but not limited to tigecycline, eravacycline, colistin, cefiderocol.
We welcome high-quality contributions, including Original Research and Review, addressing the following topics:
(1)Multicenter molecular epidemiology of A. baumannii to novel antibacterial drugs
(2)Antibiotic resistance mechanism of A. baumannii to novel antibacterial drugs
(3)In vivo evolution of A. baumannii under novel antimicrobial therapy
(4)Changes in host immune response during the treatment of A. baumannii with novel antibacterial drugs
Acinetobacter baumannii is a common pathogen and the emerged antibiotic resistance has been steadily spreading recently. Due to the rapid development of antibiotic resistance, infection with A. baumannii is difficult to treat, and it has been recognized as a global public health threat. Effective treatments for A. baumannii infection are limited because the molecular epidemiology and antibiotic resistance mechanism are not well elucidated, leading to increased mortality rates and healthcare costs.
In recent years, there have been increasing reports of MDR and XDR A. baumannii infection worldwide. Several known pathogenic factors, including lipopolysaccharide, capsular polysaccharides, protein secretion systems, efflux pumps and biofilm formation, have been reported to be involved in antibiotic resistance, environmental persistence, host-pathogen interactions, and immune evasion. However, the specific mechanism remains unclear.
The exploration of the molecular epidemiology and antibiotic resistance mechanisms of A. baumannii is of great significance for the therapeutic development of A. baumannii infection.
This Research Topic focuses on the molecular epidemiology and antibiotic resistance mechanism of A. baumannii to novel antibacterial drugs, including but not limited to tigecycline, eravacycline, colistin, cefiderocol.
We welcome high-quality contributions, including Original Research and Review, addressing the following topics:
(1)Multicenter molecular epidemiology of A. baumannii to novel antibacterial drugs
(2)Antibiotic resistance mechanism of A. baumannii to novel antibacterial drugs
(3)In vivo evolution of A. baumannii under novel antimicrobial therapy
(4)Changes in host immune response during the treatment of A. baumannii with novel antibacterial drugs
